Wealth Enhancement Advisory Services
GLUE icon

Wealth Enhancement Advisory Services’s Monte Rosa Therapeutics GLUE Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597K Sell
25,921
-1,156
-4% -$21.8K ﹤0.01% 2519
2026
Q1 		$463K Buy
27,077
+4,788
+21% +$91.6K ﹤0.01% 2379
2025
Q4 		$357K Buy
22,289
+3,746
+20% +$50.5K ﹤0.01% 2768
2025
Q3 		$137K Sell
18,543
-1,464
-7% -$7.75K ﹤0.01% 3259
2025
Q2 		$97.4K Buy
+20,007
New +$89.2K ﹤0.01% 3140

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wealth Enhancement Advisory Services's GLUE Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Monte Rosa Therapeutics (GLUE) stake by 4.3% in Q2 2026, selling an estimated $21.8K and leaving 25,921 shares worth $597K. The position accounts for ﹤0.01% of the portfolio, ranked #2519.

Wealth Enhancement Advisory Services first reported a position in GLUE in Q2 2025 and has held it in 5 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Wealth Enhancement Advisory Services held 25,921 shares of Monte Rosa Therapeutics worth $597K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 1,156 Monte Rosa Therapeutics shares in Q2 2026, an estimated $21.8K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2519 holding.
  • Wealth Enhancement Advisory Services first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.